IL1F10 and rheumatoid arthritis: Following optimisation of dosage and exposure time in vitro, in vivo studies will assess the pharmacokinetics, therapeutic efficacy, and systemic safety of exogenously administered IL-37 and IL-38 in RA animal models (43, 44).